-
公开(公告)号：US20210163417A1
公开(公告)日：2021-06-03
申请号：US16921297
申请日：2020-07-06
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/549 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/472 , C07D409/14 , C07D491/04 , C07D487/14
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号：US20180282328A1
公开(公告)日：2018-10-04
申请号：US15942321
申请日：2018-03-30
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Blake Daniels , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu
IPC: C07D471/04 , A61K45/06 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K31/55
CPC classification number: C07D471/04 , A61K31/4375 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/551 , A61K45/06 , A61P35/00 , C07D519/00
Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号：US20180282282A1
公开(公告)日：2018-10-04
申请号：US15942333
申请日：2018-03-30
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC: C07D217/22 , A61K31/472 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/549
Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号：US09890152B2
公开(公告)日：2018-02-13
申请号：US14745159
申请日：2015-06-19
Applicant: Genentech, Inc.
Inventor： Marian C. Bryan , Bryan Chan , Emily Hanan , Timothy Heffron , Hans Purkey , Richard Leonard Elliott , Robert Heald , Jamie Knight , Michael Lainchbury , Eileen M. Seward
IPC: C07D471/04 , C07D498/10 , A61K31/506 , A61K31/5377 , C07D498/08 , A61K31/541 , A61K31/538 , C07D491/107 , C07D519/00 , A61K31/5355 , A61K45/06
CPC classification number: C07D471/04 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61K31/538 , A61K31/541 , A61K45/06 , C07D491/107 , C07D498/08 , C07D498/10 , C07D519/00
Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
-
公开(公告)号：US12208088B2
公开(公告)日：2025-01-28
申请号：US17204089
申请日：2021-03-17
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Craig Stivala , BinQing Wei , Bryan K. Chan , Timothy Heffron , Michael Lainchbury , Andrew Madin , Terry Aaron Panchal , Eileen Mary Seward , Toby Blench , Matthew W. Cartwright , Elsa Amandine Dechaux , Richard Elliott , Emanuela Gancia
IPC: A61K31/437 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/513 , A61K31/5377 , A61K45/06 , A61P35/00 , C07D471/04 , C07D471/10 , C07D471/20 , C07D487/04 , C07D487/20 , C07D491/20 , C07D519/00
Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
-
Patent Agency Ranking
公开(公告)号：US20240368170A1
公开(公告)日：2024-11-07
申请号：US18769184
申请日：2024-07-10
Applicant: Genentech, Inc.
Inventor： Sushant Malhotra , Michael Siu , Weiru Wang , BinQing Wei , Aihe Zhou , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D487/04 , C07D237/28 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D417/04
Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
-
公开(公告)号：US20210277024A1
公开(公告)日：2021-09-09
申请号：US17156384
申请日：2021-01-22
Applicant: Genentech, Inc.
Inventor： Terry Kellar , Jun Liang , Sushant Malhotra , Rohan V. Mendonca , Michael Siu , Craig Stivala , John C. Tellis , BinQing Wei , Bryan K. Chan , Lewis J. Gazzard , Timothy Heffron , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D519/00 , C07D471/04 , A61P37/04
Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号：US20210253580A1
公开(公告)日：2021-08-19
申请号：US17156387
申请日：2021-01-22
Applicant: Genentech, Inc.
Inventor： Jun Liang , Sushant Malhotra , Rohan V. Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John C. Tellis , BinQing Wei , Bryan K. Chan , Joy Alison Drobnick , Lewis J. Gazzard , Timothy Heffron , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Mary Seward , Matthew W. Cartwright , Emanuela Gancia , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu
IPC: C07D487/04 , C07D513/04 , C07D519/00 , C07D487/14 , C07D498/14 , C07D401/12 , C07D401/14 , C07D405/14 , C07D498/04 , A61P37/04
Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号：US10407424B2
公开(公告)日：2019-09-10
申请号：US15942321
申请日：2018-03-30
Applicant: Genentech, Inc.
Inventor： Bryan Chan , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Blake Daniels , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca
IPC: C07D471/04 , A61K31/55 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K45/06
Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号：US09951064B2
公开(公告)日：2018-04-24
申请号：US15152947
申请日：2016-05-12
Applicant: Genentech, Inc.
Inventor： Marian C. Bryan , Bryan Chan , Francois Diederich , Jennafer Dotson , Emily Hanan , Timothy Heffron , Michael Lainchbury , Robert Heald , Eileen M. Seward
IPC: C07D471/04 , C07D519/00 , A61K31/517 , A61K31/5386 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/541
CPC classification number: C07D471/04 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K45/06 , C07D519/00
Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.056 seconds)
